Dykun Iryna, Wiefhoff Daniela, Totzeck Matthias, Al-Rashid Fadi, Jánosi R Alexander, Rassaf Tienush, Mahabadi Amir A
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
Int J Cardiol Heart Vasc. 2018 Dec 28;22:73-77. doi: 10.1016/j.ijcha.2018.12.004. eCollection 2019 Mar.
We aimed to describe whether updated low-density lipoprotein (LDL)-targets in patients with manifest coronary artery disease (CAD) led to a change in lipid profile over time.
We retrospectively included patients with manifest CAD from 2009-2010, 2012-2013, and 2015-2016 (n = 500 each). Lipid levels and medication at the different time-points as well as rate of accordance to guidelines (<100 for 2009-2010, <70 mg/dl for 2012-2013 and 2015-2016) were evaluated.
Overall, 1500 subjects (mean age: 68.4 ± 11.2 years, 75.8% male) from 813 attending primary care physicians were included. Mean LDL-level was 98.0 ± 35.7 mg/dl, whereas 34.1% reached LDL-targets according to guidelines as applied at each time-point. Reduction of LDL-goals in 2011 lead to an initial decrease in LDL from 98.3 ± 33.4 mg/dl in 2009-2010 to 93.9 ± 36.3 mg/dl in 2012-2013 (p = 0.045). This effect was no longer present in 2015-2016 (101.6 ± 36.6 mg/dl, p = 0.17). The rate of patients meeting recommended LDL-targets decreased over time (2009-2010: 56.6%, 2012-2013: 25.4%, 2015-2016: 20.2%, p < 0.0001 for trend). Likewise, the frequency of statin-intake decreased over time (93.6% in 2009-2010 to 83.7% in 2015-2016, p < 0.0001). While use of medium intensity statins was most frequent (69.4%), only 20.9% of patients with medium intensity statins reached LDL-targets according to guidelines.
In a large clinical cohort of patients with known coronary artery disease, reduction of LDL-targets in ESC-guidelines in 2011 led to an initial decline in LDL-levels, while this effect was attenuated over time with the majority of patients missing treatment goals. Higher acceptance and compliance of statin therapy is warranted to utilize its effect in secondary prevention in CAD-patients.
我们旨在描述明显冠状动脉疾病(CAD)患者中更新的低密度脂蛋白(LDL)目标是否会随时间导致血脂谱的变化。
我们回顾性纳入了2009 - 2010年、2012 - 2013年和2015 - 2016年的明显CAD患者(各n = 500)。评估了不同时间点的血脂水平和用药情况以及符合指南的比例(2009 - 2010年<100,2012 - 2013年和2015 - 2016年<70mg/dl)。
总体而言,纳入了来自813名初级保健医生的1500名受试者(平均年龄:68.4±11.2岁,75.8%为男性)。平均LDL水平为98.0±35.7mg/dl,而根据各时间点应用的指南,34.1%的患者达到了LDL目标。2011年LDL目标的降低导致LDL从2009 - 2010年的98.3±33.4mg/dl初始下降至2012 - 2013年的93.9±36.3mg/dl(p = 0.045)。这种效应在2015 - 2016年不再存在(101.6±36.6mg/dl,p = 0.17)。达到推荐LDL目标的患者比例随时间下降(2009 - 2010年:56.6%,2012 - 2013年:25.4%,2015 - 2016年:20.2%,趋势p<0.0001)。同样,他汀类药物的使用频率随时间下降(2009 - 2010年为93.6%至2015 - 2016年为83.7%,p<0.0001)。虽然中等强度他汀类药物的使用最为频繁(69.4%),但根据指南,只有20.9%使用中等强度他汀类药物的患者达到了LDL目标。
在一个大型已知冠状动脉疾病患者的临床队列中,2011年ESC指南中LDL目标的降低导致LDL水平初始下降,但随着时间的推移这种效应减弱,大多数患者未达到治疗目标。有必要提高他汀类药物治疗的接受度和依从性,以利用其在CAD患者二级预防中的作用。